Jim Weterings

Company: Bonito Biosciences

Job title: Vice President, Head of Oligonucleotide Therapeutics

Seminars:

9:00 am Workshop B: Optimizing the Oligonucleotide Structure: Unravelling the Role of Linkage & Sugar Modifications in CNS Therapeutics 9:00 am

Given the pivotal role of linkages and sugars in the development of oligonucleotide developments for CNS, this workshop will explore the latest advancements, challenges and strategies to enhance the safety and efficacy of CNS-targeted siRNAs, ASOs and RNA aptamers. Join this session to: Alter accessibility of 3’ and 5’ ends to create transient shapes improving…Read more

day: Pre-Conference Workshop Day - Track B P1

Panel Discussion: The Future of Oligonucleotide Therapeutics: Where Will the Field Be in 5 Years? 4:00 pm

How will advances in conjugation strategies, nanoparticle formulations, and tissue-specific targeting improve oligonucleotide biodistribution and efficacy? Beyond ALS, Huntington’s Disease & Alzheimer’s. What new indications, such as neurogenetic, epilepsies, neurodevelopmental and neuropsychiatric, are emerging for oligonucleotide-based therapies? What hurdles remain in scaling oligonucleotide production, and how will evolving regulatory frameworks shape the clinical and commercial…Read more

day: Day 2